article_metadata: Dongfeng Feng Yaping Guan Mingguo Liu Shuqian He Weipeng Zhao Beibei Yin Jing Liang Yan Li Jun Wang
article_metadata: 10.3389/fimmu.2021.608292
article_metadata: Front Immunol
article_metadata: 2021 May 31;12:608292.
article_metadata: atezolizumab hyperprogressive disease immune checkpoint inhibitor pembrolizumab triple-negative breast cancer
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/34135884/
article_metadata: Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Ductal / drug therapy Immune Checkpoint Inhibitors / therapeutic use Immunotherapy / methods Triple Negative Breast Neoplasms / drug therapy
article_metadata: Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Ductal / drug therapy Immune Checkpoint Inhibitors / therapeutic use Immunotherapy / methods Triple Negative Breast Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Review Aged Disease Progression Female Humans Neoplasm Metastasis Neoplasm Staging Remission Induction Treatment Outcome Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors atezolizumab pembrolizumab
article_metadata: PMC8201609
article_metadata: 34135884
article_metadata: Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature
article_metadata: 2021